Profile data is unavailable for this security.
About the company
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
- Revenue in USD (TTM)588.00k
- Net income in USD-57.90m
- Incorporated2005
- Employees56.00
- LocationaTyr Pharma Inc10240 Sorrento Valley Road, Suite 300SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 731-8389
- Fax+1 (858) 731-8394
- Websitehttps://www.atyrpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cabaletta Bio Inc | 0.00 | -89.98m | 219.33m | 136.00 | -- | 1.09 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 223.68m | 25.00 | -- | 3.72 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Nkarta Inc | 0.00 | -107.91m | 225.08m | 150.00 | -- | 0.4967 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 228.25m | 112.00 | -- | 0.6844 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 228.73m | 19.00 | -- | 1.72 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
| XBiotech Inc | 0.00 | -35.01m | 230.00m | 94.00 | -- | 1.17 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Onkure Therapeutics Inc | 0.00 | -56.54m | 234.51m | 8.00 | -- | 0.7643 | -- | -- | -16.82 | -16.82 | 0.00 | 23.00 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 234.53m | 88.00 | -- | 1.37 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 234.56m | 145.00 | -- | 1.57 | -- | 3.26 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Amarin Corporation plc (ADR) | 241.02m | -39.35m | 236.44m | 275.00 | -- | 0.4449 | -- | 0.981 | -0.0959 | -0.0959 | 0.5876 | 1.29 | 0.3032 | 0.4387 | 2.05 | 876,440.00 | -4.95 | -4.48 | -7.02 | -6.54 | 56.46 | 75.70 | -16.32 | -8.59 | 2.11 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| aTyr Pharma Inc | 588.00k | -57.90m | 236.48m | 56.00 | -- | 2.90 | -- | 402.18 | -0.9047 | -0.9047 | 0.0092 | 1.08 | 0.0049 | -- | 0.4034 | 10,500.00 | -48.51 | -45.45 | -53.89 | -52.74 | -- | -- | -9,846.26 | -784.19 | -- | -- | 0.0202 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Caribou Biosciences Inc | 11.48m | -148.12m | 242.68m | 158.00 | -- | 0.863 | -- | 21.15 | -1.65 | -1.65 | 0.128 | 3.11 | 0.0286 | -- | 5.08 | 72,626.59 | -36.94 | -- | -39.76 | -- | -- | -- | -1,290.81 | -- | -- | -1,321.46 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| 2Seventy Bio Inc | 44.12m | -156.25m | 243.59m | 274.00 | -- | 1.04 | -- | 5.52 | -3.06 | -3.06 | 0.8417 | 4.56 | 0.0721 | -- | 1.42 | 161,021.90 | -25.54 | -- | -28.17 | -- | 66.39 | 91.76 | -354.16 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Compass Therapeutics Inc. | 850.00k | -47.24m | 247.66m | 32.00 | -- | 1.70 | -- | 291.37 | -0.3573 | -0.3573 | 0.0064 | 1.06 | 0.0051 | -- | -- | 26,562.50 | -28.22 | -41.75 | -29.94 | -46.41 | -- | -- | -5,557.88 | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Climb Bio Inc | 0.00 | -64.20m | 254.16m | 9.00 | -- | 1.14 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to aTyr Pharma Inc's reporting currency: US Dollar USD
59.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Federated Global Investment Management Corp.as of 30 Sep 2024 | 14.67m | 19.35% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 10.35m | 13.66% |
| Point72 Asset Management LPas of 14 Oct 2024 | 5.04m | 6.65% |
| Logos Global Management LPas of 30 Jun 2024 | 3.00m | 3.96% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.64m | 3.48% |
| Tikvah Management LLCas of 30 Jun 2024 | 2.46m | 3.25% |
| Checkpoint Capital LPas of 30 Jun 2024 | 1.95m | 2.57% |
| Alyeska Investment Group LPas of 30 Jun 2024 | 1.87m | 2.46% |
| Woodline Partners LPas of 30 Jun 2024 | 1.68m | 2.22% |
| Citadel Advisors LLCas of 30 Jun 2024 | 1.50m | 1.98% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
